

Interventions to Facilitate Smoking Cessation

Okuyemi K S, MD, MPH

University of Minnesota Medical School, Minneapolis, Minnesota

Nollen N L, PHD

University of Kansas School of Medicine, Kansas City, Kansas

Ahluwalia J S, MD, MPH

University of Minnesota Medical School, Minneapolis, Minnesota

Abstract

Tobacco use, primarily cigarette smoking, is the leading cause of preventable morbidity and mortality in the United States, and nearly one third of those who try a cigarette become addicted to nicotine. Family physicians, who see most of these patients in their offices every year, have an important opportunity to decrease smoking rates with office-based interventions. The U.S. Public Health Service recommends that primary care physicians use the five A's (Ask, Advise, Assess, Assist, and Arrange) model when treating patients with nicotine addiction. Physicians can improve screening and increase cessation rates by asking patients about tobacco use at every office visit. Behaviour modification can improve long-term smoking cessation success; even brief (five minutes or less) advice on smoking cessation during an office visit can increase cessation rates. The effectiveness of non-pharmacologic treatments generally is lower; therefore, pharmacotherapy is recommended for smokers who are willing to attempt cessation, unless medical contraindications exist. The pharmacologic agents approved by the U.S. Food and Drug Administration for treatment of tobacco dependence include bupropion (a non-nicotine therapy) and nicotine replacement therapies in the form of a gum, patch, nasal spray, inhaler, and lozenge. These agents have similar long-term success rates.

Am Fam Physician 2006;74:262-71, 276. Copyright © 2006 American Academy of Family Physicians.

SA Fam Pract 2007;49(1): 28-38

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation (smoking cessation interventions)	Evidence rating	References	Quit rates at six months (%)*	Comments
Single therapies				
Brief physician advice	A	2	2 to 10	Brief intervention is five minutes or less in a single visit.
Telephone counseling	A	37, 40	5 to 19	Overall effect likely to be small compared with no intervention. There is no additional benefit when combined with other interventions (e.g., physician advice, pharmacotherapy). Indirect evidence suggests that "quitlines" can be useful in smoking cessation.
Self-help materials	B	38, 40	7 to 27	Successful interventions usually require multiple (up to six per week) contacts with self-help materials near the time of the quit date. Materials that are tailored to individual smokers may be more effective than standard materials. ³⁸
Nicotine patch	A	12	8 to 21	Less potential for addiction compared with gum
Nicotine spray	A	12, 33	30	Higher potential for addiction compared with other NRTs ¹⁵
Nicotine inhaler	A	12, 33	23	Mimics hand-to-mouth motion of smoking
Nicotine lozenge	A	16	24	Similar results among smokers regardless of success or failure of previous pharmacologic therapy ¹⁷
Nicotine gum in highly dependent smokers	A	12	24	Quit rates were higher in specialized cessation clinics than in primary care settings; higher potential for addiction than the patch ^{6,11}
Bupropion (Wellbutrin SR)	SR A	20, 22, 23	21 to 30	Initial concerns about increased risk of seizures have not been confirmed.
Combination therapies				
Nicotine patch plus nicotine gum	B	25	28	Combination more effective than either agent alone
Nicotine patch plus nicotine spray	B	28	37 (at three months)	Combination more effective than either agent alone
Nicotine patch plus nicotine inhaler	B	26	25	Combination more effective than either agent alone
Nicotine patch plus bupropion	B	23	35	Combination more effective than patch alone but not bupropion alone

NRT = nicotine replacement therapy; SR = sustained release.

*-Quit rates cannot be compared across treatment types because of the substantial differences among studies.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see page 215 or <http://www.aafp.org/afpsort.xml>.

Introduction

Tobacco use, primarily cigarette smoking, is the leading cause of preventable morbidity and mortality in the United States.¹ Primary care physicians have an opportunity to offer office-based smoking cessation interventions to the 70 percent of smokers who visit their offices every year.² Goals of the Healthy People 2010³ initiative include increasing to 75 percent the proportion of family physicians who routinely provide smoking cessation counseling. Studies have shown that physicians and their staffs can be trained to successfully deliver office-based smoking cessation interventions,⁴ and that these interventions significantly improve smoking cessation rates.^{4,5}

Screening and Diagnosis

The 2000 Agency for Health Care Policy and Research (AHCPR; now the Agency for Healthcare Research and Quality) clinical practice guideline on treating tobacco use and dependence urges physicians to treat tobacco use as a chronic disease.² It recommends

that physicians use the five A's (Ask, Advise, Assess, Assist, and Arrange) model (Table 1²) when treating patients with nicotine addiction.

The first step, asking about tobacco use at every visit, has been shown to improve screening and cessation rates; a nurse or other staff member can do this when taking the patient's vital signs.² Physicians should establish office-wide systems to enhance consistent identification of smokers. This includes asking questions to identify current, former, or never-smokers. For example, patients should be asked, "Do you currently use any form of tobacco?" Those who answer "no" should then be asked, "Have you regularly used any form of tobacco in the past?" Merely asking, "Are you a smoker?" may not identify occasional or light smokers, some of whom do not consider themselves smokers.

Treatment

One of the barriers to addressing tobacco use in the clinical setting is that physicians have not been reimbursed for much of their work in this area. In

the USA, the Medicare Part B insurance plan recently began covering smoking cessation counseling. The coverage is limited to Medicare patients who have diseases or adverse health effects linked to their tobacco use and to those whose tobacco use affects their metabolism or medication dosages. More information on the coverage of tobacco use counseling is available at <http://www.cms.hhs.gov/Transmittals/downloads/R818CP.pdf>.

Physicians should give patients who use tobacco brief advice on why they should attempt cessation and then assess their willingness to quit. Physicians can offer motivation and support to help patients modify their behaviors. However, pharmacologic treatment has a higher success rate⁶ than nonpharmacologic treatment and should be offered to patients unless a clinical contraindication exists.²

NONPHARMACOLOGIC THERAPY

The "stages of change" model⁷ is a useful tool for assessing a patient's willingness to quit using tobacco. This model

Table 1

The Five A's Model for Facilitating Smoking Cessation	
Five A's	Implementation suggestions
Ask about tobacco use during every office visit.	Include questions about tobacco use when assessing the patient's vital signs. Placing tobacco-use status stickers on patient charts, noting tobacco use in electronic medical records, or using computer reminder systems also may be helpful.
Advise all smokers to quit.	Advice should be: Clear: "I think it is important for you to quit smoking now. Cutting down or changing to light cigarettes is not enough." Strong: "As your physician, I need to tell you that smoking cessation is one of the most important decisions you can make for your health." Personalized: physicians should talk with patients about how smoking has affected their health, children, or other family members; the social and economic costs of smoking; and the patient's readiness to quit.
Assess the patient's willingness to quit.	Assess the patient's willingness to quit by asking, "On a scale from 0 to 10, with 0 being 'not at all motivated' and 10 being 'extremely motivated,' how motivated are you to quit smoking?" Use the patient's level of motivation to determine the next step: If the patient is willing to make a quit attempt, offer medication, brief counseling, and self-help resources and schedule a follow-up visit. If the patient is unwilling to quit, identify why the patient is not motivated. Explore what he or she likes and does not like about smoking and the potential advantages and disadvantages of quitting. Identify the patient's core values (e.g., health, being a role model for children) and how smoking affects these values.
Assist the patient in his or her attempt to quit.	Help the patient make a quit plan: Set a quit date, ideally within two weeks of the office visit. Request encouragement and support from family and friends. Anticipate triggers and cues to smoking and identify alternative coping strategies. Help the patient change his or her environment: Throw away cigarettes, matches, lighters, and ashtrays; launder clothing; vacuum home and car. Avoid smoking in places where the patient spends a lot of time (e.g., home, work, car). Avoid other smokers and drinking alcohol. Provide basic information about smoking and cessation (e.g., addictive nature of smoking, importance of complete abstinence, possible withdrawal symptoms). Recommend pharmacotherapy, unless contraindications exist (Table 2), and behavior therapy for smoking cessation. Provide supplementary self-help materials (Table 3).
Arrange follow-up contact.	Follow-up should occur within the first week after the quit date. A second follow-up contact is recommended within the first month. Further follow-up visits should be scheduled as needed. During a follow-up visit, success should be congratulated. If the patient has relapsed, review the circumstances and elicit a new commitment to quit. Consider referral for more intensive treatment. Follow-up contact can be by telephone, e-mail, or in person.

Information from reference 2.

entails changing behaviour through a process of five motivational stages: (1) precontemplation (not planning to quit within the next six months), (2) contem-
 plation (considering quitting within the next six months), (3) preparation (planning to quit within the next 30 days), (4) action (successfully quitting for less than six months), and (5) maintenance (successfully quitting for at least six months). Interventions based on the stages of change model have been

Table 2

FDA-Approved Medications for Smoking Cessation				
Advantages	Disadvantages	Contraindications	Usual dosage	Cost per day*
Bupropion SR (Wellbutrin SR)				
Non-nicotine tablet; easy to use; may be used with NRTs	May cause insomnia, dry mouth, headache, tremors, nausea, or anxiety	Pregnancy category B Avoid in patients with seizure disorders, bulimia or anorexia nervosa, or history of head trauma and in patients currently using bupropion or an MAOI.	150 mg per day for three days, then twice per day for seven to 12 weeks. Start treatment one to two weeks before quit date.	\$4.33 per day (two 150-mg tablets per day)
Nicotine gum				
Over-the-counter availability; flexible dosing; delivers nicotine faster than the patch.	No food or drink 15 minutes before use; frequent dosing May cause jaw pain, mouth soreness, dyspepsia, or hiccups	Pregnancy category D; may use in pregnant women if non-pharmacologic measures fail and if the benefit outweighs the risk Avoid in patients with dental problems or temporomandibular joint syndrome. Cardiovascular precautions†	Patients who smoke < 15 cigarettes per day: one 2-mg piece of gum every one to two hours Patients who smoke ≥ 15 cigarettes per day: one 4-mg piece of gum every one to two hours	2 mg: 9.33 per day (average of 16 pieces per day) 4 mg: 10.33 per day (average of 16 pieces per day)
Nicotine inhaler				
Flexible dosing; mimics hand-to-mouth action of smoking; few side effects	Frequent dosing necessary May cause mouth and throat irritation	Pregnancy category D Cardiovascular precautions†	Six to 16 10-mg (only delivers 4 mg of nicotine) cartridges per day for three months; taper dosages over six to 12 weeks.	9.50 per day (average of 12 cartridges per day)
Nicotine lozenge				
Over-the-counter availability; flexible dosing; delivers nicotine faster than the patch	Frequent dosing necessary; no food or drink 15 minutes before use May cause mouth soreness or dyspepsia	Pregnancy category D Cardiovascular precautions†	Weeks 1 to 6: one lozenge every one to two hours Weeks 7 to 9: one lozenge every two to four hours Weeks 10 to 12: One lozenge every four to eight hours Patients who smoke their first cigarette of the day within 30 minutes of awakening should use the 4-mg dose; others should use the 2-mg dose.	2 or 4 mg: 8.88 per day (average of 16 lozenges per day)
Nicotine patch (transdermal)				
Over-the-counter availability; daily application; overnight use may reduce early morning cravings; few side effects	Less flexible dosing; slow delivery of nicotine May cause skin irritation or sleep problems if worn at night	Pregnancy category D Cardiovascular precautions†	Patients who smoke more than 10 cigarettes per day: 21 mg every 24 hours for six to eight weeks, step down to 14 mg every 24 hours for two to four weeks, then to 7 mg every 24 hours for two to four weeks Patients who smoke 10 cigarettes or less per day: 15 mg every 16 hours for six weeks	21 mg: 4.00 per day (one patch per day) 14 mg: 3.40 per day (one patch per day) 7 mg: 3.40 per day (one patch per day) 15 mg: 3.60 per day (one patch per day)
Nicotine nasal spray				
Flexible dosing; fastest delivery of nicotine among NRTs; reduces cravings within a few minutes	Frequent dosing necessary May cause nose and eye irritation or cough Most addictive of the NRTs	Pregnancy category D Cardiovascular precautions†	One or two 0.5-mg doses in each nostril every hour for three to six months; taper doses over four to six weeks	16.00 per day (average of 16 sprays per day)
<p>FDA = U.S. Food and Drug Administration; SR = sustained release; NRT = nicotine replacement therapy; MAOI = monoamine oxidase inhibitor. *Estimated cost to the pharmacist based on average wholesale prices in Red book. Montvale, N.J.: Medical Economics Data, 2005. Cost to the patient will be higher, depending on prescription filling fee. †-Avoid in the month after myocardial infarction, serious arrhythmias, or unstable angina, unless the benefits outweigh the risks.</p>				

shown to enhance motivation and predict cessation.⁸

For patients who are unwilling to quit, physicians should identify reasons for their resistance and address these reasons. Patients who are willing to attempt cessation should receive specific advice about how to proceed (e.g., setting a quit date, pharmacotherapy). Studies² have shown that even brief (five minutes or less) advice on cessation from a physician during an office visit improves cessation rates compared with no advice.

PHARMACOTHERAPY

The pharmacologic agents approved by the U.S. Food and Drug Administration (FDA) for the treatment of tobacco dependence (*Table 2⁹*) have similar long-term success rates.⁹ These agents include five forms of nicotine replacement therapy (NRT; e.g., gum, patch, nasal spray, inhaler, lozenge) and bupropion sustained release (Wellbutrin SR).⁹

Nicotine Gum

A meta-analysis that included randomized controlled studies of specialized cessation clinics showed that patients using nicotine gum had higher success rates at six months than those using placebo gum (27 versus 18 percent).² However, studies¹⁰ of general medical practices showed that the six-month success rate of nicotine gum was no different than that of placebo (12 percent). The higher cessation rate associated with nicotine gum in specialized smoking cessation clinics may be attributed to more in-depth counseling, better adherence to treatment, better trained counselors, and participants who are more motivated to quit. Nicotine gum is available over the counter in 2- and 4-mg doses. The 4-mg dose is recommended for those who smoke 15 or more cigarettes per day.² No definite benefits have been noted beyond eight weeks.¹¹

Nicotine Patch (Transdermal)

A meta-analysis¹² showed that the patch has a six-month success rate of 8 to 21 percent compared with 4 to 14 percent for placebo, and a 12-month success rate of 10 to 16 percent compared with 6 to 16 percent for placebo. Treatment beyond eight weeks has not been shown to increase effectiveness. Patches are available over the counter in 15- and 21-mg doses. Step-down doses of 14 and 7 mg may accompany the 21-mg dose, although data have not shown that this step-down approach

adds benefit. Those who smoke more than 10 cigarettes per day should use the 21-mg dose.² Although there were earlier concerns about the safety of nicotine patches, specifically in patients with myocardial infarction, the FDA has concluded and studies have shown that there are no adverse effects associated with the nicotine patch in smokers with a history of coronary heart disease.^{13,14}

Nicotine Nasal Spray

A meta-analysis² showed that the nicotine nasal spray had a six-month success rate of 31 percent compared with 14 percent for placebo. One spray into each nostril equals one dose; each spray contains 0.5 mg of nicotine. Patients should use one to two doses per waking hour for three to six months.² The nicotine nasal spray seems to be the most addictive of the NRTs.¹⁵ If a patient presents with withdrawal symptoms after abrupt discontinuation of treatment, the physician should consider initiating a four- to six-week tapering period. Tapering may be achieved by halving the dose every week. The most common side effects include nasal irritation, runny nose, sneezing, throat irritation, coughing, and watery eyes. Patients usually develop tolerance to these effects within the first week, however.

Nicotine Inhaler

A meta-analysis² showed that the inhaler had a six-month success rate of 23 percent compared with 11 percent for placebo. Adverse events are generally mild and consist of throat irritation and cough. The nicotine inhaler is unique in that it mimics the hand-to-mouth motion of smoking. The inhaler consists of a cartridge attached to a plastic mouthpiece. The cartridge contains 10 mg of nicotine (but only delivers 4 mg) plus 1 mg of menthol. The recommended dose is six to 16 cartridges per day for three months, then taper for six to 12 months. The nicotine is absorbed in the mouth rather than in the lungs.²

Nicotine Lozenge

Randomized clinical trials^{16,17} have shown that the nicotine lozenge (2 mg) has a six-week success rate of 46 percent compared with 30 percent for placebo and a six-month success rate of 24 percent compared with 14 percent for placebo. Results were similar for the 4-mg dose. The nicotine lozenge is similar to nicotine gum in that it is administered orally; however, it delivers about 25 percent more nicotine than the gum.¹⁸ The 4-mg dose is recommended

for those who smoke their first cigarette of the day within 30 minutes of awakening; otherwise, the 2-mg dose should be used. At least nine lozenges per day are recommended for the first six weeks.

Bupropion SR

Randomized controlled trials have demonstrated that bupropion SR is effective in clinical practice settings^{19,20} and in hospital employees²¹ and minorities.²² Six-month success rates were 21 to 30 percent for bupropion SR compared with 10 to 19 percent for placebo. Common adverse effects are generally mild and consist of insomnia and dry mouth. Less common side effects include headache, nausea, and anxiety. Bupropion is contraindicated for patients with a history of seizures, anorexia or bulimia, or head trauma, and in those who currently use bupropion or monoamine oxidase inhibitors. The drug also should be avoided in patients with increased seizure risk (e.g., excessive use of alcohol or sedatives, such as benzodiazepines; addiction to opiates, cocaine, or stimulants; tight control of diabetes). Because the risk of seizure is dose dependent, the total daily dosage of bupropion SR should not exceed 300 mg.

Combination Pharmacotherapy

Combining the nicotine patch with a self-administered NRT (e.g., gum, spray, inhaler) is more effective than a single NRT.² A randomized trial²³ showed that bupropion SR combined with the patch was more effective than the patch alone but not significantly more effective than bupropion SR alone. However, a recent study including mostly veterans²⁴ showed that combining bupropion SR with the patch did not significantly increase success rates compared with the patch alone. Other studies²⁵ have shown that combining the patch with the gum significantly increases cessation success rates (by up to 50 percent) compared with the patch alone. Similarly, studies have shown that combining the patch with the inhaler²⁶ or nasal spray^{27,28} significantly increases cessation success rates compared with each therapy alone. Therefore, combination pharmacotherapy should be considered for smokers who are unable to quit because of significant cravings or withdrawal symptoms despite adequate doses of a single therapy.

Other Recommended Pharmacotherapies

The AHCPR clinical practice guideline² recommends clonidine and nor-*tripty-*


line as second-line agents for smoking cessation. Controlled studies on these agents are limited,^{29,30} and neither drug is FDA-approved for smoking cessation. Clonidine and nor-triptyline should be considered only for patients who have failed first-line therapies or are unable to use them because of contraindications.

ALTERNATIVE THERAPIES

A number of complementary and alternative therapies such as hypnosis and acupuncture have been considered for smoking cessation. The AHCPR did not find sufficient evidence to recommend hypnosis or acupuncture for smoking cessation.² A Cochrane review³¹ of

nine studies provided no evidence that hypnosis was effective for smoking cessation. Another Cochrane review³² of 22 randomized trials showed that there was no clear evidence that acupuncture or its variations (e.g., acupressure, laser therapy, electrostimulation) were effective for smoking cessation.

Figure 1: Algorithm for the identification and treatment of patients who smoke.



(NRT = nicotine replacement therapy; SR = sustained release.)
Adapted with permission from Okuyemi KS, Ahluwalia JS, Harris KJ. Pharmacotherapy of smoking cessation. Arch Fam Med 2000;9:279.

CHOOSING A TREATMENT

Few data exist comparing the effectiveness of the approved pharmacotherapies for smoking cessation. The Safety, Tolerability, Efficacy, Price, Simplicity (STEPS) approach can be used to guide physicians when they are choosing a therapy.³³ NRTs are considered generally safe with mild adverse effects. They all have similar cardiovascular precautions, and all are pregnancy category D. Bupropion SR also is relatively safe with precautions as discussed above. However, product-specific characteristics may make some NRTs less suitable for certain patients. For example, the gum is not appropriate for patients with dental or jaw problems because it requires special chewing techniques and high frequency of use. The adhesive on the patch may be affected by humid weather. The patch also should be avoided in patients with systemic eczema.

The only study³⁴ that has compared the effectiveness of various NRTs reported similar results for the gum, patch, spray, and inhaler. No study has compared the lozenge with other NRTs. Although one study²³ reported that bupropion was more effective than the patch, this finding has not been replicated. Bupropion costs slightly less than NRTs, and the patch appears to be the most convenient therapy to use among the NRTs. In one randomized controlled trial,³⁴ compliance was highest for the patch (82 percent) compared with the gum (38 percent), the spray (15 percent), and the inhaler (11 percent). However, the effectiveness of these therapies may be lower in "real-world" settings because clinical trial participants are self-selected and, therefore, are more motivated to quit smoking and willing to comply with frequent follow-ups. Also, those in placebo groups typically receive substantially more counseling than those in real-world settings. These factors may produce higher quit rates in patients taking placebo than are typically found in unaided cessation attempts. *Figure 1*³⁵ is an algorithm for identifying and treating patients who smoke.

Follow-up

Relapse (in general or, more specifically, smoking on seven consecutive days or once each week over two consecutive weeks)³⁶ is common. Physicians can use a number of brief strategies to help prevent relapse. At a minimum, patients should be encouraged to identify their smoking cues and triggers and decide

on alternative coping strategies before they attempt to quit smoking. During follow-up visits, physicians should assess patients' progress, congratulate success, and encourage continued cessation. Patients also should be encouraged to discuss the benefits of cessation including health benefits; the successes they have had (e.g., duration of abstinence, effective coping strategies); and problems or barriers to cessation (e.g., negative mood, irritability, alcohol, other smokers).²

For patients who have experienced a relapse, it is recommended that the physician review with the patient the circumstances surrounding the relapse and elicit a new commitment to quit. It also is important to counsel these patients on the proper use of pharmacotherapy and to arrange a timely follow-up visit (i.e., about one week after the new quit date). Behaviour modification for smoking cessation also should be considered. Finally, patients should be reminded that a relapse is an opportunity for them to learn what tempted them to smoke and how to cope better with similar situations in the future.

On average, most smokers attempt

to quit smoking four or five times before cessation is successful.² Data suggest that approximately 6 to 38 percent of smokers who relapse will attempt to quit again within the next year.² Given this relatively high rate of reattempts, it is important for physicians to maintain contact with a patient who smokes, even after relapses, to facilitate a future smoking cessation attempt when a patient is most motivated to quit. For this reason, arranging follow-up care for smoking cessation (the last step of the five A's model) is highly important. The follow-up should occur within one week of the patient's quit date, because the risk of relapse is highest during the first few days of abstinence.²

Considerable data show that additional follow-up (e.g., face-to-face contact; letters or telephone conversations³⁷; self-help materials³⁸ beyond initial brief advice) significantly increases cessation success rates.³⁹ Self-help brochures and print materials from professional organizations are readily available. The patient information handout with this article can be given to patients as an adjunct to initial brief advice and follow-up. In addition to office-based self-help resources, a grow-

Table 3: Self-help resources for smoking cessation

American Academy of Family Physicians

Web site: <http://www.aafp.org/x27811.xml>

Telephone: 800-274-2237

Address: 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2672

American Cancer Society

Web site: http://www.cancer.org/docroot/PED/content/PED_10_13X_Guide_for_Quitting_Smoking.asp

Telephone: 800-ACS-2345 (800-227-2345)

American College of Obstetricians and Gynecologists

Web site: http://www.acog.org/departments/dept_web.cfm?recno=13

Telephone: 202-638-5577

Address: 409 12th St. SW, Washington, DC 20090-6920

American Heart Association

Web site: <http://www.americanheart.org/presenter.jhtml?identifier=3018961>

Telephone: 800-AHA-USA1 (800-242-8721)

Address: 7272 Greenville Ave., Dallas, TX 75231

American Lung Association

Web site: <http://www.lungusa.org/site/pp.asp?c=dvLUK9o0E&b=33484>

Telephone: 800-LUNGUSA (800-586-4872)

Address: 61 Broadway, 6th Floor, New York, NY 10006

Nicotine Anonymous

Web site: www.nicotine-anonymous.org

Telephone: 415-750-0328

Address: 419 Main St., PMB #370, Huntington Beach, CA 94159-1777

National Cancer Institute

Web site: www.nci.nih.gov/cancertopics/tobacco/quitting-and-prevention

Telephone: 800-4-CANCER (800-422-6237)

QuitNet


Web site: <http://www.quitnet.com>

QuitSmokingSupport


Web site: <http://www.quitsmokingsupport.com>

ing number of free telephone "quitlines" and Internet-based resources are available for persons who want to quit smoking.⁴⁰ **Table 3** includes a list of self-help resources for smoking cessation.

Prognosis

Smoking cessation significantly reduces morbidity and mortality from smoking.² The degree of improvement, however, depends on the disease process and the amount of damage present as well as the reversibility of this damage at the time of cessation. Former smokers reduce their risk of developing coronary heart disease by 50 percent within one year of quitting.² After four years, this risk becomes equal to that of never-smokers.² The decrease in cancer risk varies with the type of cancer involved. For example, the risk of lung cancer in former smokers always remains higher than that in never-smokers. However, this risk decreases progressively and considerably with the number of years the former smoker remains abstinent. In addition to reducing morbidity and mortality, smoking cessation is among the most cost-effective measures in primary care.⁴¹ The estimated cost per life-year saved is \$2,000 for smoking cessation compared with \$50,000 per life-year saved for breast cancer mammography.² 

See CPD Questionnaire, page 48

 This article has been peer reviewed

The Authors

KOLAWOLE S. OKUYEMI, M.D., M.P.H., is director of the Health Disparities Research Program and is associate professor in the Department of Family Medicine and Community Health at the University of Minnesota Medical School, Minneapolis. At the time this article was written, he was associate professor of family medicine and preventive medicine and associate chair for research in the Department of Family Medicine at the University of Kansas School of Medicine, Kansas City. Dr. Okuyemi received his medical degree from the University of Ilorin in Nigeria and a master's of public health degree from the University of Kansas School of Medicine. He completed a family medicine residency at the University of Kansas Medical Center, Kansas City.

NICOLE L. NOLLEN, PH.D., is assistant professor in the Department of Preven-

tive Medicine and Public Health at the University of Kansas School of Medicine, where she also completed a postdoctoral fellowship. Dr. Nollen received her doctorate in counseling psychology from the University of Missouri-Kansas City.

JASJIT S. AHLUWALIA, M.D., M.P.H., is executive director of the Office of Clinical Research at the University of Minnesota Academic Health Center and is professor in the Department of Medicine at the University of Minnesota Medical School. At the time this article was written, Dr. Ahluwalia was professor of preventive medicine, family medicine, internal medicine, and pediatrics and chair of the Department of Preventive Medicine and Public Health at the University of Kansas School of Medicine. Dr. Ahluwalia received his medical degree and a master's of public health degree from Tulane University, New Orleans, La., and a master's of health policy degree from Harvard School of Public Health, Boston, Mass. He completed an internal medicine residency at the University of North Carolina at Chapel Hill and a general internal medicine fellowship at Harvard Medical School.

Address correspondence to Kolawole S. Okuyemi, M.D., M.P.H., University of Minnesota Medical School, Center for Clinical Research, G254 Mayo Memorial Building, MMC 451, 420 Delaware St. SE, Minneapolis, MN 55455 (e-mail: kokuyemi@umn.edu). Reprints are not available from the authors.

Author disclosure: Nothing to disclose.

REFERENCES

- Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000 [Published correction appears in JAMA 2005;293:293-4]. JAMA 2004;291:1238-45.
- Fiore MC. Treating tobacco use and dependence. Rockville, Md.: U.S. Department of Health and Human Services, Public Health Service, 2000. Accessed February 22, 2006, at: <http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat2.section.7741>.
- U.S. Department of Health and Human Services. Healthy people 2010. Washington, D.C.: U.S. Department of Health and Human Services, 2000.
- Wadland WC, Stoffelmayr B, Berger E, Crombach A, Ives K. Enhancing smoking cessation rates in primary care. J Fam Pract 1999;48:711-8.
- Katz DA, Muehlenbruch DR, Brown RB, Fiore MC, Baker TB, for the AHRQ Smoking Cessation Guideline Study Group. Effectiveness of a clinic-based strategy for implementing the AHRQ smoking cessation guideline in primary care. Prev Med 2002;35:293-301.
- Benowitz NL. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addiction. N Engl J Med 1988;319:1318-30.
- Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol 1983;51:390-5.
- Farkas AJ, Pierce JP, Zhu SH, Rosbrook B, Gilpin EA, Berry C, et al. Addiction versus stages of change models in predicting smoking cessation. Addiction 1996;91:1271-80.
- Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA 1999;281:72-6.
- Lam W, Sze PC, Sacks HS, Chalmers TC. Meta-analysis of randomised controlled trials of nicotine chewing-gum. Lancet 1987;2:27-30.
- Hughes JR, Gust SW, Keenan R, Fenwick JW, Skoog K, Higgins ST. Long-term use of nicotine vs placebo gum. Arch Intern Med 1991;151:1993-8.
- Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation [Update appears in Cochrane Database Syst Rev 2004;(3):CD000146]. Cochrane Database Syst Rev 2002;(4):CD000146.
- Joseph AM, Norman SM, Ferry LH, Prochaska AV, Westman EC, Steele BG, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996;335:1792-8.
- Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease. Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med 1994;154:989-95.
- Sutherland G, Stapleton JA, Russell MA, Jarvis MJ, Hajek P, Belcher M, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992;340:324-9.
- Shiffman S, Dresler CM, Hajek P, Gilbert SJ, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 2002;162:1267-76.
- Shiffman S, Dresler CM, Rohay JM. Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy [Published correction appears in Addiction 2004;99:273]. Addiction 2004;99:83-92.
- Choi JH, Dresler CM, Norton MR, Strahs KR. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 2003;5:635-44.
- Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med 2003;163:2337-44.
- Hurt RD, Sachs DP, Glover ED, Offord KT, Johnston JA, Dale LC, et al. A com-

- parison of sustained-release bupropion and placebo for smoking cessation. *N Engl J Med* 1997;337:1195-202.
21. Dalsgarth OJ, Hansen NC, Soes-Petersen U, Evald T, Hoegholm A, Barber J, et al. A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. *Nicotine Tob Res* 2004;6:55-61.
 22. Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. *JAMA* 2002;288:468-74.
 23. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. *N Engl J Med* 1999;340:685-91.
 24. Simon JA, Duncan C, Carmody TP, Hudes ES. Bupropion for smoking cessation: a randomized trial. *Arch Intern Med* 2004;164:1797-803.
 25. Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. *Prev Med* 1995;24:41-7.
 26. Bohadana A, Nilsson F, Rasmussen T, Martinet Y. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. *Arch Intern Med* 2000;160:3128-34.
 27. Croghan GA, Sloan JA, Croghan IT, Novotny P, Hurt RD, DeKrey WL, et al. Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. *Nicotine Tob Res* 2003;5:181-7.
 28. Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up [Published correction appears in *BMJ* 1999;318:764]. *BMJ* 1999;318:285-8.
 29. Glassman AH, Covey LS, Dalack GW, Stetner F, Rivelli SK, Fleiss J, et al. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. *Clin Pharmacol Ther* 1993;54:670-9.
 30. Hall SM, Reus VI, Munoz RF, Sees KL, Humfleet G, Hartz DT, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. *Arch Gen Psychiatry* 1998;55:683-90.
 31. Abbot NC, Stead LF, White AR, Barnes J, Ernst E. Hypnotherapy for smoking cessation. *Cochrane Database Syst Rev* 2000;(2):CD001008.
 32. White AR, Rampes H, Ernst E. Acupuncture for smoking cessation. *Cochrane Database Syst Rev* 2002;(2):CD000009.
 33. Nielsen K, Fiore MC. Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation. *Prev Med* 2000;30:209-16.
 34. Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. *Arch Intern Med* 1999;159:2033-8.
 35. Okuyemi KS, Ahluwalia JS, Harris KJ. Pharmacotherapy of smoking cessation. *Arch Fam Med* 2000;9:270-81.
 36. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations [Published correction appears in *Nicotine Tob Res* 2003;5:603]. *Nicotine Tob Res* 2003;5:13-25.
 37. Stead LF, Lancaster T. Telephone counselling for smoking cessation [Update appears in *Cochrane Database Syst Rev* 2003;(1):CD002850]. *Cochrane Database Syst Rev* 2001;(2):CD002850.
 38. Lancaster T, Stead L, Silagy C, Sowden A. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. *BMJ* 2000;321:355-8.
 39. Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. *Arch Intern Med* 1995;155:1933-41.
 40. Zhu SH, Anderson CM, Tedeschi GJ, Rosbrook B, Johnson CE, Byrd M, et al. Evidence of real-world effectiveness of a telephone quitline for smokers. *N Engl J Med* 2002;347:1087-93.
 41. Curry SJ, Grothaus LC, McAfee T, Pabiniak C. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. *N Engl J Med* 1998;339:673-9.

JAR Car
Best in the business

THE ONLY CAR HIRE COMPANY AT

R85.00

PER DAY

**Conditions
 Apply**

**Tel: 031 305 8717
 Cell: 076 760 6803**

117 Gale street, Durban